Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Current Assets (2016 - 2025)

Ascendis Pharma A (ASND) has disclosed Current Assets for 10 consecutive years, with $1.3 billion as the latest value for Q4 2025.

  • Quarterly Current Assets rose 13.87% to $1.3 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 billion through Dec 2025, up 13.87% year-over-year, with the annual reading at $1.3 billion for FY2025, 13.87% up from the prior year.
  • Current Assets hit $1.3 billion in Q4 2025 for Ascendis Pharma A, up from $1.1 billion in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $1.3 billion in Q4 2025 to a low of $756.1 million in Q4 2023.
  • Historically, Current Assets has averaged $1.0 billion across 5 years, with a median of $942.2 million in 2022.
  • Biggest five-year swings in Current Assets: dropped 19.75% in 2023 and later skyrocketed 49.93% in 2024.
  • Year by year, Current Assets stood at $921.9 million in 2021, then rose by 2.2% to $942.2 million in 2022, then dropped by 19.75% to $756.1 million in 2023, then surged by 49.93% to $1.1 billion in 2024, then rose by 13.87% to $1.3 billion in 2025.
  • Business Quant data shows Current Assets for ASND at $1.3 billion in Q4 2025, $1.1 billion in Q4 2024, and $756.1 million in Q4 2023.